Wall Street Experts
ver. ZuMIgo(08/25)
Inhibrx Biosciences, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 2
EBIT TTM (mln): 1 654
| index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
| Rok finansowy |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Przychód (mln) |
7 |
8 |
8 |
9 |
13 |
7 |
2 |
2 |
0 |
| Przychód Δ r/r |
0.0% |
19.2% |
-5.7% |
21.2% |
40.9% |
-44.4% |
-69.4% |
-17.4% |
-88.9% |
| Marża brutto |
-154.9% |
-220.9% |
-346.1% |
-426.9% |
-473.8% |
62.3% |
-30.7% |
33.8% |
100.0% |
| EBIT (mln) |
-12 |
-20 |
-30 |
-44 |
-67 |
-77 |
-129 |
-219 |
-331 |
| EBIT Δ r/r |
0.0% |
62.4% |
49.6% |
48.1% |
54.3% |
13.5% |
68.6% |
69.8% |
51.2% |
| EBIT (%) |
-182.2% |
-248.2% |
-393.5% |
-480.7% |
-526.6% |
-1074.6% |
-5928.2% |
-12178.9% |
-165724.0% |
| Koszty finansowe (mln) |
0 |
2 |
1 |
6 |
11 |
5 |
16 |
32 |
13 |
| EBITDA (mln) |
-12 |
-19 |
-29 |
-43 |
-67 |
-77 |
-129 |
-218 |
1,703 |
| EBITDA(%) |
-178.4% |
-242.8% |
-383.6% |
-468.5% |
-526.6% |
-1074.6% |
-5928.2% |
-12112.8% |
851675.0% |
| Podatek (mln) |
-5 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
| Zysk Netto (mln) |
-8 |
-19 |
-31 |
-51 |
-76 |
-82 |
-145 |
-241 |
1,688 |
| Zysk netto Δ r/r |
0.0% |
135.1% |
60.3% |
64.9% |
47.2% |
8.1% |
77.6% |
66.2% |
-799.2% |
| Zysk netto (%) |
-124.0% |
-244.6% |
-415.5% |
-565.3% |
-590.5% |
-1147.6% |
-6667.9% |
-13408.9% |
843786.0% |
| EPS |
-0.23 |
-0.68 |
-1.15 |
-1.41 |
-2.99 |
-2.15 |
-3.62 |
-5.12 |
114.01 |
| EPS (rozwodnione) |
-0.23 |
-0.68 |
-1.15 |
-1.41 |
-2.99 |
-2.15 |
-3.62 |
-5.12 |
112.62 |
| Ilośc akcji (mln) |
37 |
29 |
27 |
37 |
25 |
38 |
40 |
47 |
15 |
| Ważona ilośc akcji (mln) |
37 |
29 |
27 |
37 |
25 |
38 |
40 |
47 |
15 |
| Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |